Trial Profile

COMBINE: Effect of Combined Pharmacotherapies and Behavioral Interventions

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acamprosate (Primary) ; Naltrexone (Primary)
Indications Alcoholism
Focus Therapeutic Use
Acronyms COMBINE

Most Recent Events

01 Jul 2022 Results of an analysis assessed the predictors of abstinence, no heavy drinking days, and a 2-level reduction published in the Alcoholism - Clinical and Experimental Research
22 Mar 2019 New trial record
13 Mar 2019 Results of (n= 1169) of pooled analysis of this and other two (NCT00210925, NCT01146613)multicenter trials assessing drinking rise levels as outcomes published in the JAMA Psychiatry

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com